Subscribe to our newsletter

Richard G. Jung Joins Corrona Board of Directors

CorEvitas is now part of Thermo Fisher Scientific. Read More.

SOUTHBOROUGH, MA ― Corrona, a leader in real world evidence and consulting in the auto-immune field, announced today that Richard (Rick) G. Jung has been elected as a member of the Board of Directors of the company. Corrona is a portfolio company of the health care investment firm, Great Point Partners, based in Greenwich CT.

Rick is currently serving as CEO and Chairman of Clinicient, a leading provider of automated, integrated revenue and clinical cycle services to physical, speech, occupational and rehabilitation therapy markets, based in Portland, OR.

“I am thrilled that Rick will be joining the Corrona Board of Directors. He has a great background that compliments that of our existing Board members. His experience in the electronic medical record space will be invaluable to us as we start to look at opportunities to link related data sources and increase the value we bring to our clients,” said Raymond H. Hill, Executive Chairman of Corrona.

Noah Rhodes, Managing Director of Great Point Partners noted “Rick possesses a unique and diverse background in health care. We are excited about his contributions to the Corrona Board of Directors as the company continues its next chapter of growth.”

“I am excited to be joining the Board of Directors of Corrona,” said Mr. Jung, “Corrona is doing innovative work with real world patient and clinical data in the autoimmune disease space. With access to leading observational data sets, Corrona is well positioned to help companies understand how their drugs are used in the real world.”

Mr. Jung is a member of the Board of Directors of Clinicent, where he has served since 2007. He previously was President and CEO of HealthFx, and COO of Medsphere Systems Corp. Earlier on in his career he served at both athenahealth, and US Healthcare.

About Corrona

Corrona was founded in 2000 by leading physicians dedicated to advancing and improving the care of patients with chronic autoimmune diseases. Its mission is to advance research and improve the quality of patient care through world-class observational cohorts. Corrona provides data and research results to all biopharmaceutical companies with an interest in particular therapeutic areas of coverage. Corrona data is used to assist in comparative effectiveness, post market safety reporting, and commercial applications. Corrona is advised by experienced academic and clinical physicians throughout the country with a wide range of experiences. Read more at

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point Partners at 203-971-3300 or